Emalex Biosciences Inc. closed an upsized and oversubscribed $250 million series D funding round intended to support a soon-to-start phase III trial and preparations for potential commercialization of ecopipam, its first-in-class drug for Tourette syndrome, a neurological disorder characterized by involuntary motor and vocal tics.

It was a good week for companies focused on minimally invasive brain surgery. Monteris Medical Corp. received $35 million in a series D equity financing and a $38 million debt facility to support market adoption and clinical research on its Neuroblate system, a laser ablation system that provides a minimally invasive option for brain surgery. Nico Corp. also raised additional funds, with a $12.5 million oversubscribed round for its devices, which do not require cutting through the brain but instead use the natural folds of the brain to reach abnormalities.

Delphinus Medical Technologies Inc. raised $30.4 million in a series D fundraising round to support worldwide commercialization of its Softvue 3D whole breast ultrasound tomography system. Both new and existing investors kicked in funds including Arboretum Ventures, Beringea, North Coast Technology Investors, Venture Investors, Hopen Life Science Ventures and Waycross Ventures.

Xeltis BV raised $15 million in series D2 funding to develop its restorative vascular access device for patients with chronic kidney disease who are on hemodialysis. The investment in this technology, called the Axess graft, came from Hong Kong-based China Grand Pharmaceutical and Healthcare Holdings Ltd. (Grand Pharma). The deal focuses mainly on commercializing Axess, but also involves other new products in the field of hemodialysis developed as part of the Xeltis technology platform. The commitment from Grand Pharma includes equity investment and product licensing, representing Xeltis’ first commercial deal and its first funding from an Asian concern.

Carmot Therapeutics Inc. has raised $160 million in series D financing to support a trio of early to midstage clinical programs focused on treating diabetes and obesity with peptide-based small-molecule incretin receptor modulators.

AI-enabled drug discovery company Insilico Medicine Ltd. has raised $60 million in a series D round to support expansion of its pipeline.

AI-enabled drug discovery company Insilico Medicine Ltd. has raised $60 million in a series D round to support expansion of its pipeline. The Hong Kong and New York-based company will use the proceeds to support clinical testing of its lead asset, a potential treatment for idiopathic pulmonary fibrosis (IPF), as well as the advancement of its Pharma.AI platform.

Biofourmis Inc. secured $300 million in a series D financing led by General Atlantic, with participation by CVS Health and existing investors. The round lifted the Boston-based company’s valuation to more than $1 billion and unicorn status, according to executives. Biofourmis will use the funds to drive next-stage growth in its virtual care offerings and digital therapeutics (DTx).

Valuations in the med-tech space lately call into question the old medical adage: “If you hear hoofbeats, think horses.” These days, you would be wise to consider unicorns in the differential diagnosis. Two new companies achieved the formerly rare status just this week. Viz.ai Inc.’s closing today of a $100 million series D financing propelled it into the stratosphere with a $1.2 billion valuation, joining Bostongene LLC which completed its own $150 million round Wednesday.